arrow
H

Hironori Koga

kurume university
H指数:47
被引数:8,706

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hepatic arterial infusion of autologous CD34+cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial
2024-12-012
OAAI
Exploring the role of obesity-induced exosome secretion and associated proteins in endometrial cancer pathogenesis: A roadmap for prevention through exosome inhibition
2024-03-220
PRE
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study
2023-11-282
OAAI
A Phase 2, Prospective, Multicenter, Single-arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-stage Hepatocellular Carcinoma: TACTICS-L Trial
2023-06-0536
OAAI
Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors
2023-02-246
OAAI
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data

使用真实世界数据,阿特珠单抗联合贝伐单抗治疗肝细胞癌后雷莫昔单抗的意义

2022-11-167
PRE
The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma
2022-11-0622
PRE
Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma
2022-10-118
OAAI